公开(公告)号：US20230366894A1

公开(公告)日：2023-11-16

申请号：US18028235

申请日：2021-09-30

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Jennifer Marie Theresia Anna Meessen ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler

IPC: G01N33/74

CPC classification number: G01N33/74 ,  G01N2333/58 ,  G01N2440/38 ,  G01N2800/326

Abstract: The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.

公开(公告)号：US20230055005A1

公开(公告)日：2023-02-23

申请号：US17821937

申请日：2022-08-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Bernhard Eckert ,  Michael Gerg ,  Johann Karl ,  Martin Kaufmann ,  Julia Riedlinger ,  Magdelena Swiatek-de-Lange ,  Lars Hillringhaus ,  Klaus Hirzel ,  Marcus-Rene Lisy

IPC: C07K16/36 ,  G01N33/574 ,  G01N33/86

Abstract: The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.

公开(公告)号：US20210140971A1

公开(公告)日：2021-05-13

申请号：US17152212

申请日：2021-01-19

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Johann Karl ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing whether a pregnant subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not, said method comprising the steps of determining the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject, and comparing the determined amount of the biomarker to a reference. Further, the present invention relates to the in vitro use of the biomarker IGFBP-7, or of at least one detection agent which specifically binds to IGFBP-7 in a sample of a pregnant subject for assessing whether said subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not. Also encompassed by the present invention is a device adapted to carry out the method of the present invention.

公开(公告)号：US20190353666A1

公开(公告)日：2019-11-21

申请号：US16217612

申请日：2018-12-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Dirk Block ,  Johann Karl ,  Peter Kastner ,  Ursula-Henrike Wienhues-Thelen ,  Roberto Latini ,  Serge Masson ,  Andre Ziegler ,  Edelgard Kaiser ,  Stefan Palme ,  Markus Thomas ,  Simona Barlera

IPC: G01N33/68

Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.

公开(公告)号：US20180364230A1

公开(公告)日：2018-12-20

申请号：US16111347

申请日：2018-08-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Johann Karl ,  Ursula Kunert ,  David Morgenstern ,  Nina Meissler ,  Marion Niessner ,  Magdalena Swiatek-de Lange

IPC: G01N33/564 ,  G01N33/574 ,  C07K16/46

Abstract: The disclosure relates to an in vitro method for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.

公开(公告)号：US10094826B2

公开(公告)日：2018-10-09

申请号：US15673976

申请日：2017-08-10

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Stefan Weiser ,  Johann Karl ,  Ursula Kunert ,  Florian Grupp

IPC: G01N33/53 ,  G01N33/564 ,  G01N33/563 ,  G01N33/58

Abstract: Described is a method aiding in the assessment of rheumatoid arthritis (“RA”). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, including measuring the concentration of anti-CCP and anti-PIK 3CD and correlating the concentrations determined to the absence or presence of RA. Also disclosed is the use of a marker panel including anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method. Also described is the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).

公开(公告)号：US20170227552A1

公开(公告)日：2017-08-10

申请号：US15581587

申请日：2017-04-28

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Roberto Latini ,  Serge Masson ,  Dirk Block ,  Christian Zaugg ,  Thomas Dieterle ,  Edelgard Kaiser ,  Johann Karl ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68

Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.

公开(公告)号：US20160169895A1

公开(公告)日：2016-06-16

申请号：US15046525

申请日：2016-02-18

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Norbert Wild ,  Marie-Luise Hagmann ,  Johann Karl ,  Julia Riedlinger ,  Markus Roessler ,  Michael Tacke

IPC: G01N33/573

CPC classification number: G01N33/573 ,  G01N33/54306 ,  G01N33/57411 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57442 ,  G01N33/57449 ,  G01N33/57488 ,  G01N2333/922 ,  G01N2800/52 ,  G01N2800/7028 ,  G16H50/30 ,  Y02A90/26

Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.

公开(公告)号：US20160018411A1

公开(公告)日：2016-01-21

申请号：US14639496

申请日：2015-03-05

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Christoph Ehret ,  Johann Karl ,  Ralf Roeddiger ,  Wolfgang Rollinger ,  Magdalena Swiatek-de Lange

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  A61B5/0205 ,  G01N2333/96411 ,  G01N2333/96433 ,  G01N2800/12 ,  G01N2800/32

Abstract: The present invention relates to a method for differentiating in a patient who suffers from acute shortness of breath (acute dyspnea) between pulmonary disease and cardiac disease. The method is based on measuring the levels of seprase and of a cardiac marker in a sample from said patient. Further envisaged are kits and devices adapted to carry out the method of the present invention.

Abstract translation: 本发明涉及在患有肺疾病与心脏病之间的急性呼吸急促（急性呼吸困难）的患者中进行区分的方法。 该方法基于测量来自所述患者的样品中seprase和心脏标志物的水平。 进一步设想的是适于实施本发明方法的试剂盒和装置。

公开(公告)号：US20150355199A1

公开(公告)日：2015-12-10

申请号：US14835821

申请日：2015-08-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Alfred Engel ,  Andreas Gallusser ,  Johann Karl ,  Peter Kastner ,  Wolfgang Obermeier ,  Monika Soukupova

IPC: G01N33/68 ,  C07K16/18 ,  G01N33/543

CPC classification number: C07K16/18 ,  C07K14/472 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  G01N33/54306 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/2814 ,  G01N2800/30 ,  G01N2800/52

Abstract: The present invention relates to an assay for specific detection of complement factor H-related protein 1 (CFHR1) in a sample from a subject, as well as kits and agents related thereto.

Abstract translation: 本发明涉及用于特异性检测来自受试者的样品中的补体因子H相关蛋白1（CFHR1）的测定，以及与其相关的试剂盒和试剂。